Hereditary Hemorrhagic Telangiectasia
📧 Sign up to get email alerts when something new happens for Hereditary Hemorrhagic Telangiectasia.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2026-08-04EMA Application withdrawn: Orblid (bevacizumab) — Laboratoires Delbert
The EMA has withdrawn the application for Orblid (bevacizumab) by Laboratoires Delbert for hereditary telangiectasia/hemorrhagic conditions.
-
CLINICAL_TRIALS withdrawal · 2026-04-13Clinical Trial Update: A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia [Phase 1]
The Phase 1 trial of TER-1754 for hereditary hemorrhagic telangiectasia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2013-04-29Clinical Trial Update: Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) [Phase 1]
This entry notes a Phase 1 clinical trial evaluating ranibizumab for recurrent nosebleeds in patients with hereditary hemorrhagic telangiect…